Tenax Therapeutics (TENX)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	111.45 mm	111.45 mm	111.45 mm	111.45 mm	111.45 mm	111.45 mm
Cash burn (monthly)	(no burn)	(no burn)	3.78 mm	2.90 mm	2.32 mm	1.38 mm
Cash used (since last report)	n/a	n/a	10.43 mm	7.99 mm	6.41 mm	3.82 mm
Cash remaining	n/a	n/a	101.02 mm	103.46 mm	105.04 mm	107.63 mm
Runway (months of cash)	n/a	n/a	26.7	35.7	45.2	77.7

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

TENX institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	28	18	+55.6%
Opened positions	13	14	-7.1%
Closed positions	3	2	+50.0%
Increased positions	1	1	–
Reduced positions	2	0	NEW

13F shares	Current	Prev Q	Change
Total value	8.46 bn	1.88 bn	+350.4%
Total shares	9.49 mm	12.17 mm	-22.0%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Vivo Opportunity Fund	6.25 mm	$25.88 mm	0.0%
Intracoastal Capital	479.73 k	$840.00 k	0.0%
Adage Capital Management	369.10 k	$1.59 mm	0.0%
Venrock Healthcare Capital Partners III	355.22 k	$1.47 mm	0.0%
Biotechnology Value Fund L P	340.66 k	$1.41 mm	0.0%
BVF	339.55 k	$2.10 bn	NEW
Dellora Investments	234.79 k	$1.48 mm	NEW
VR Adviser	208.33 k	$1.29 bn	NEW
Vivo Capital	208.33 k	$1.29 bn	0.0%
JHG Janus Henderson	166.67 k	$1.03 bn	NEW

Largest transactions	Shares	Bought/sold	Change
T. Rowe Price	0.00	-3.75 mm	EXIT
BVF	339.55 k	+339.55 k	NEW
Dellora Investments	234.79 k	+234.79 k	NEW
VR Adviser	208.33 k	+208.33 k	NEW
JHG Janus Henderson	166.67 k	+166.67 k	NEW
MS Morgan Stanley	74.44 k	+74.44 k	NEW
Vestal Point Capital	55.19 k	+55.19 k	NEW
Stonepine Capital Management	0.00	-50.00 k	EXIT
ADAR1 Capital Management	34.69 k	-27.73 k	-44.4%
Millennium Management	26.81 k	+26.81 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

TENX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
16 May 25	Chrisopher Thomas Giordano	Stock Option Common Stock	Grant	Acquire A	No	No	5.89	1,400,000	8.25 mm	1,400,000
16 May 25	Stuart Rich	Stock Option Common Stock	Grant	Acquire A	No	No	5.89	625,000	3.68 mm	625,000
10 Dec 24	June Sherie Almenoff	Stock Option Common Stock	Grant	Acquire A	No	No	5.94	100,000	594.00 k	100,000

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Tenax Therapeutics Q1 EPS $(0.28) Misses $(0.19) Estimate

14 May 25

Tenax Therapeutics (NASDAQ:TENX) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.19) by 47.37 percent. This is a 91.03 percent increase over losses of $(3.12) per share

Tenax Therapeutics Q4 2024 GAAP EPS $(0.18) Beats $(0.42) Estimate

25 Mar 25

Tenax Therapeutics (NASDAQ:TENX) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.42) by 57.14 percent. This is a 98.48 percent increase over losses of $(11.84) per share

Press releases

From Benzinga Pro

Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

25 Mar 25

Successfully Completed Private Placements with Aggregate Gross Proceeds of Approximately $125 Million to Support Advancement of Two Registrational Studies for TNX-103 in PH-HFpEF and Fund Operations through 2027 Phase 3